ImmuCell Corporation

NasdaqCM:ICCC

Sector

🛒 Consumer Staples

Industries

🍔 Meat

🔬 Clinical Trials

🥛 Dairy & Milk

🐶 Pet Food

💉 Vaccines

Location

United States

Market Cap

USD 63.09 M

Share Price

USD 6.75

Avg Daily Volume

27,368

Change (1 day)

-0.59%

Change (1 year)

54.82%

Change (YTD)

31.07%

ImmuCell Corporation Market Capitalization on June 27, 2025: USD 63.09 M

ImmuCell Corporation Market Capitalization is USD 63.09 M on June 27, 2025, a 71.05% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

ImmuCell Corporation 52-week low Market Capitalization is USD 71.04 M on June 27, 2025, which is 12.59% above the current Market Capitalization.
ImmuCell Corporation 52-week low Market Capitalization is USD 30.09 M on June 27, 2025, which is -52.30% below the current Market Capitalization.
ImmuCell Corporation average Market Capitalization for the last 52 weeks is USD 41.55 M.

Daily

From:

To:

Zoom:

Key data

Date	Market Capitalization	Share Price	Share Price	Price to Earnings Ratio (P/E)

NasdaqCM: ICCC

ImmuCell Corporation

CEO	Mr. Michael F. Brigham
IPO Date	May 5, 1987
Location	United States
Headquarters	56 Evergreen Drive
Employees	69
Sector	🛒 Consumer Staples
Industries Meat 🔬 Clinical Trials 🥛 Dairy & Milk 🐶 Pet Food 💉 Vaccines

Description

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.